Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.22M
Gross Margin
54.43%
TTM Avg
58.30%
3Y Avg
57.46%
5Y Avg
45.97%
Market Cap
$6.88M
Gross Margin
64.28%
TTM Avg
69.38%
3Y Avg
65.33%
5Y Avg
71.21%
Market Cap
$6.82M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
Market Cap
$7.31M
Gross Margin
14.92%
TTM Avg
28.44%
3Y Avg
28.69%
5Y Avg
27.44%
Market Cap
$6.80M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
Market Cap
$6.65M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.06M | 0.00% | 0.00% | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.22M | 54.43% | 58.30% | 57.46% | 45.97% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | 64.28% | 69.38% | 65.33% | 71.21% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.82M | 80.62% | 90.31% | -419.28% | -4158.68% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 14.92% | 28.44% | 28.69% | 27.44% |
| Aclarion, Inc. (ACON)vs › | $6.80M | -291.27% | -237.54% | -120.88% | -89.07% |
| KALA BIO, Inc. (KALA)vs › | $7.36M | 0.00% | 0.00% | 8.55% | 24.65% |
| Longeveron Inc. (LGVN)vs › | $7.46M | 69.76% | 72.87% | 54.39% | 49.20% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.65M | 0.00% | 0.00% | 0.00% | 0.00% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.53M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
